Building the World's Antiviral Defense SystemBefore the Next Pandemic

Building out our antiviral toolkit proactively rather than reactively

What is ViRx@Stanford

A Stanford initiative building the world's antiviral defense system

Antivirals ready before the next outbreak — not after it.

ViRx@Stanford

BE READI !

Stanford BiosEcuRity & PandEmic PrepAreDness Initiative

Emerging Virus
Discovery Engine
Antiviral Candidates
Preclinical Validation
Clinical Translation
Global Deployment

The Threat

Each pandemic has cost millions of lives and trillions in economic damage. The world has responded reactively, every time.

63years
1918Influenza~50M deaths
22years
1981HIV/AIDS>40M deaths
11years
2003SARS8K cases, global alarm
5years
2014Ebola11K deaths, W. Africa
?years
2019COVID-197M+ deaths · $14T loss

Next Unknown

Are we ready?

The Vision

A world free from viral threats

Healthy families. Thriving communities. Economies that never again grind to a halt. This is the future ViRx@Stanford is building — one where humanity meets the next virus from a position of strength.

A smiling girl riding on her father's shoulders under a blue sky, mother looking on

Why Antivirals

Vaccines take years. Viruses don’t wait.

Antivirals are the fast, flexible first line of defense — deployable in the critical early window before a vaccine can ever exist.

Speed

Ready in the first days of an outbreak — not the first year. Antivirals close the deadly gap before vaccines arrive.

Breadth

Broad-spectrum candidates can work across virus families, including threats we haven’t seen yet.

First Line

When a new virus emerges, antivirals are what stand between an outbreak and a pandemic.

Our Unique Solution

For each virus: Three potential lines of attack.

ViRx@Stanford doesn’t bet on a single drug. We combine three complementary antiviral strategies — SyneRx sets the example.

Host-targeting Antivirals
Modulators of Host Response
Direct Acting AntiviralSyneRx
Researcher reviewing a DNA model on a tablet — antiviral discovery in the lab

BIOdefense Strategic Hosting and Investment for EarLy Delivery (BIOSHIELD)

Goal

Establish proactive, long-term partnerships with companies developing next-generation biodefense countermeasures.

INVESTMENT & ACCESS MODEL

  • Advanced procurement of countermeasures

  • Priority purchase rights for future doses

  • Direct investment in companies

  • Investment in scalable manufacturing

Core Capabilities

  • Seats on government advisory committees

  • Annual convening of biodefense leaders

  • Lab space, personnel and infrastructure

  • Hosting high-potential companies

Leadership

The team to execute a mission this big

World-class scientists and operators with a proven track record of translating discovery into real-world impact.

Advisory Board

Guided by the architects of modern medicine

  • Portrait of Stéphane Bancel, MBA

    Stéphane Bancel, MBA

    CEO, Moderna Therapeutics

  • Portrait of Terrence Blaschke, MD

    Terrence Blaschke, MD

    Professor of Medicine & Molecular Pharmacology, Emeritus · Stanford University

  • Portrait of Gail Cassell, PhD

    Gail Cassell, PhD

    Division of Global Health Equity · Brigham and Women's Hospital

  • Portrait of Nancy Chang, PhD

    Nancy Chang, PhD

    CEO & Chairperson, Ansun BioPharma

  • Portrait of Harry Greenberg, MD

    Harry Greenberg, MD

    Emeritus Associate Dean of Research · Stanford University School of Medicine

  • Portrait of Ted Love, MD

    Ted Love, MD

    Immediate Past Chair, Biotechnology Innovation Organization (BIO) · Former President & CEO, Global Blood Therapeutics

  • Portrait of Matthew Nicoletti

    Matthew Nicoletti

    Chief Strategy Officer & Director, Perpetuals.com Ltd.

  • Portrait of Peter Palese, PhD

    Peter Palese, PhD

    Professor & Chair, Microbiology · Mount Sinai School of Medicine

  • Portrait of Charles Rice, PhD

    Charles Rice, PhD

    Professor of Virology, Rockefeller University · Nobel Laureate

  • Portrait of Douglas Richman, MD

    Douglas Richman, MD

    Professor of Pathology and Medicine (Active Emeritus), U.C. San Diego

  • Portrait of Lucy Shapiro, PhD

    Lucy Shapiro, PhD

    Professor of Microbiology, Stanford Univ.; Natl. Security Task Force on Pandemic

  • Portrait of Chris Somerville, PhD

    Chris Somerville, PhD

    Program Officer, Coefficient Giving, National Academy of Sciences

  • Portrait of Ralph Welborn, PhD

    Ralph Welborn, PhD

    Co-Founder and Managing Director of SunasiAI

  • Portrait of Richard Whitley, PhD

    Richard Whitley, PhD

    Professor/Co-Director, Pediatric Infectious Diseases · UAB

Global Impact

Stanford at the core. An antiviral defense network spanning the globe.

Collaborating hubs across continents, anywhere a threat can emerge

World map showing ViRx@Stanford collaborating hubs across five continents
Global hubs
7
Spin-off companies
1(9 in the making)
Antiviral candidates
18+

Funding & Support

    • National Institutes of Health
    • U.S. Department of War
    • Stanford University Human-Centered Artificial Intelligence
    • Falk Foundation
    • Coefficient Giving
    • Harrington Discovery Institute, University Hospitals, Cleveland, Ohio
    • FAST GRANTS
    • Tang Family Foundation
    • Durst Family
    • Capella

Partnership

A transformational gift, a generational return

Partner at the scale of the problem. Each level unlocks a distinct piece of the global antiviral defense system.

$10M+

Catalyst

Fund a full antiviral discovery program against a priority threat.

$50M+

Architect

Build out a platform pillar — AI engine, preclinical, or clinical translation.

$100M+

Founding Partner

Name and endow the defense system. Define humanity’s antiviral future.

Your Legacy

Build the antiviral defense system that protects every generation after ours

Let's talk about what your partnership can make possible.

ViRx@Stanford logo

© 2026 ViRx@Stanford. All rights reserved.